PolyPeptide Group AI Visibility Market Strategy Report - Peptide API Manufacturing

Answer Capsule

PolyPeptide Group holds 14.5% valid recommendation coverage in the October 2026 LLM Authority Index benchmark for Peptide API Manufacturing, ranking third of seven tracked brands. The company is visible in 23.5% of qualified AI responses but converts only a portion of that presence into recommendations, and it holds just 2 rank-one placements across 200 qualified observations. Its clearest strength is a 12.5% top-three rate that outpaces several larger-presence competitors; its clearest gap is the distance to category leader Bachem, which holds 67.0% coverage and 44.0% rank-one placement. The biggest opportunity sits in converting its existing presence into first-position recommendations within the Brand Recommendation cluster.

Who This Report Is For

This report is written for PolyPeptide Group commercial, marketing, and category leadership teams, and for peptide API buyers and analysts tracking how AI-powered discovery surfaces present CDMO suppliers at the recommendation stage.

Report Card

Executive Summary

PolyPeptide Group enters October 2026 as a mid-tier presence in the Peptide API Manufacturing benchmark, with 23.5% raw mention presence and 14.5% valid recommendation coverage. The gap between those two figures is the central story: the brand appears in roughly one in four qualified AI responses but is recommended in fewer than one in seven. That conversion gap places it behind Bachem (92.5% presence, 67.0% coverage) and AmbioPharm (37.0% presence, 22.5% coverage) on recommendation-stage visibility.

The benchmark shows PolyPeptide Group improved meaningfully against September 2026, rising 8.7 points from 5.8% to 14.5% coverage, a move the benchmark flags as significant. Against the July 2026 baseline of 9.8%, the gain is 4.7 points and stays inside normal month-to-month variation. The September-to-October recovery is real, but it rests on a modest base of 29 valid recommendations and should be read as directional rather than as an established trend.

Placement is where PolyPeptide Group diverges most sharply from the category leader. Its top-three rate of 12.5% is respectable for a mid-tier brand, but its rank-one rate of 1.0% means it is almost never the first supplier AI systems name. Bachem holds a 44.0% rank-one rate on the same 200 observations. The brand is being shortlisted, not chosen first.

Sentiment is a relative strength. PolyPeptide Group carries a net sentiment score of 0.766, with 36 positive mentions, 11 neutral mentions, and zero negative mentions. That places it mid-pack among tracked brands, above CordenPharma Peptides (0.64) and CSBio (0.67), but below Biosynth Peptide Division (0.933) and Bachem (0.854). The absence of negative framing is a stable foundation.

Platform behavior is uneven. Google AI Overviews is the strongest surface for PolyPeptide Group, delivering 11 valid recommendations and a 14.86% coverage rate on 74 observations. Google AI Mode follows with 6 valid recommendations and a 14.63% coverage rate. ChatGPT and Copilot show weaker conversion: ChatGPT delivered 1 valid recommendation from 7 present observations, and Copilot delivered 4 from 5 present observations. The brand is present across all six tracked platforms but converts inconsistently.

The clearest opportunity is converting existing presence into first-position recommendations. PolyPeptide Group already appears in enough qualified responses to compete for top-three placement. The gap is in rank-one conversion, where the brand holds 2 placements against Bachem's 88. Closing even a fraction of that gap would materially change its recommendation-stage position.

What PolyPeptide Group Is Winning

Questions This Section Answers

• What does PolyPeptide Group's September-to-October coverage recovery show?
• How strong is PolyPeptide Group's sentiment position across the October dataset?
• Where does PolyPeptide Group place when it is recommended?

PolyPeptide Group's strongest evidence-backed win is its September-to-October recovery. Valid recommendation coverage rose 8.7 points from 5.8% to 14.5%, a move the benchmark flags as significant. That recovery reversed a September contraction in which presence rose while recommendations fell, indicating the brand converted a modestly larger presence into a meaningfully larger recommendation share in October.

The second win is sentiment stability. With 36 positive mentions, 11 neutral mentions, and zero negative mentions, PolyPeptide Group carries no negative framing in the October dataset. Its net sentiment score of 0.766 is mid-pack but clean, and the absence of cautionary or negative mentions means the brand is not fighting a framing problem.

The third win is top-three placement relative to presence. PolyPeptide Group's 12.5% top-three rate exceeds its 14.5% coverage rate by a narrow margin, meaning that when the brand is recommended, it tends to land in the top three rather than in lower positions. Its average recommended rank of 2.69 is competitive with AmbioPharm (2.66) and better than CPC Scientific (3.38) and CordenPharma Peptides (3.27).

These are real but narrow wins. The brand does not hold category leadership on any tracked metric, and its gains rest on a base of 29 valid recommendations.

Where PolyPeptide Group Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why does PolyPeptide Group's rank-one conversion lag so far behind Bachem?
• Which platforms convert PolyPeptide Group's presence into recommendations least effectively?
• What can't yet be measured about PolyPeptide Group because of cluster concentration?

The clearest gap is rank-one conversion. PolyPeptide Group holds 2 rank-one placements across 200 qualified observations, a 1.0% rank-one rate. Bachem holds 88 rank-one placements and a 44.0% rank-one rate. AmbioPharm holds 4 rank-one placements. The brand is being shortlisted but is almost never the first supplier AI systems name when buyers ask for a peptide API manufacturer.

The second gap is presence-to-recommendation conversion. PolyPeptide Group appears in 47 of 200 qualified observations (23.5% presence) but receives valid recommendations in only 29 (14.5% coverage). That means roughly 18 appearances, or 38% of its presence, do not convert into a recommendation. Bachem converts 134 recommendations from 185 appearances, a 72% conversion rate. AmbioPharm converts 45 from 74, a 61% conversion rate. PolyPeptide Group converts 29 from 47, a 62% conversion rate, which is competitive with AmbioPharm but well below Bachem.

The third gap is platform inconsistency. On ChatGPT, PolyPeptide Group appears in 7 of 15 observations but receives only 1 valid recommendation, a 6.67% coverage rate. On Copilot, it appears in 5 of 30 observations and receives 4 valid recommendations, a 13.33% coverage rate. On Gemini, it appears in 5 of 28 observations and receives 2 valid recommendations, a 7.14% coverage rate. These are materially weaker than its Google AI Overviews performance (11 valid recommendations from 74 observations, 14.86% coverage). The brand's recommendation strength is concentrated on Google surfaces and thin on ChatGPT, Copilot, and Gemini.

The fourth gap is cluster concentration. All 200 qualified observations fall into the Brand Recommendation cluster. The Pricing & Value and Multi-Brand Comparison clusters contained zero qualified observations in October 2026. PolyPeptide Group cannot yet be measured on how AI systems handle price sensitivity or head-to-head supplier comparisons, which are the questions buyers ask closer to decision.

Biggest Opportunity

Questions This Section Answers

• What prompts decide rank-one placement for PolyPeptide Group?
• How far is PolyPeptide Group's rank-one position from Bachem's?

The single biggest opportunity is converting PolyPeptide Group's existing presence into first-position recommendations within the Brand Recommendation cluster. The brand already appears in 23.5% of qualified responses and holds a 12.5% top-three rate. The gap is not visibility; it is rank-one conversion. With only 2 rank-one placements against Bachem's 88, PolyPeptide Group is being named as an option but not as the answer.

The path runs through the prompts that already surface the brand. The benchmark's cluster prompt examples include high-intent questions such as "best peptide company," "What is the most reputable company for peptides?," "Which company makes the best peptides?," and "Who is the most reputable peptide supplier?" These are the prompts where rank-one placement is decided. PolyPeptide Group's 2.69 average recommended rank suggests it is landing in second or third position on the prompts where it is recommended. Moving from second to first on a subset of those prompts is the clearest available gain.

Competitive Landscape

Questions This Section Answers

• How does PolyPeptide Group's top-three and rank-one rate compare to other peptide API manufacturers?
• Where does PolyPeptide Group's average recommended rank and sentiment sit in the tracked set?

Bachem holds dominant recommendation-stage strength in Peptide API Manufacturing, with 67.0% valid recommendation coverage and a 44.0% rank-one rate. PolyPeptide Group sits third in the category by coverage, behind Bachem and AmbioPharm, with a top-three rate that places it fourth.

Average recommended rank covers rank-eligible recommendations only.

PolyPeptide Group's 12.50% top-three rate places it third in the category, ahead of CPC Scientific, Biosynth Peptide Division, CordenPharma Peptides, and CSBio. Its 1.00% rank-one rate is tied with Biosynth and well behind Bachem and AmbioPharm. The table shows a brand that is consistently shortlisted but rarely named first.

Prompt Evidence

Google AI Overviews / Brand Recommendation Prompt: "best peptide company" Result: PolyPeptide Group appeared in the response and received a valid recommendation, contributing to its strongest platform performance.

ChatGPT / Brand Recommendation Prompt: "Who is the most reputable peptide supplier?" Result: PolyPeptide Group was present in the response but did not receive a valid recommendation, reflecting its weak ChatGPT conversion rate.

Google AI Mode / Brand Recommendation Prompt: "What is the most reliable peptide company?" Result: PolyPeptide Group received a valid recommendation and landed in a top-three position, consistent with its Google AI Mode coverage rate of 14.63%.

Perplexity / Brand Recommendation Prompt: "Which company makes the best peptides?" Result: PolyPeptide Group was present and received a valid recommendation, with an average recommended rank of 3.2 on Perplexity.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map the specific prompts where PolyPeptide Group appears but does not convert, and identify which competitors take the recommendation when the brand is displaced.

Phase 2: Recommendation Readiness Plan Prioritize the Brand Recommendation prompts where PolyPeptide Group already holds top-three placement and build a plan to move those placements to rank one.

Phase 3: Owned Answer Layer Buildout Strengthen the owned pages and structured content that AI systems retrieve when forming peptide API supplier recommendations, with emphasis on the ChatGPT, Copilot, and Gemini surfaces where conversion is weakest.

Phase 4: Citation / Authority Layer Development Develop the third-party and specialist source footprint that supports recommendation-stage visibility, since the benchmark shows citations are broadly distributed across more than 550 domains.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track PolyPeptide Group's coverage, top-three rate, rank-one rate, and sentiment month over month to confirm whether the October recovery holds and whether rank-one conversion improves.

Why This Matters

AI presence alone is not enough. PolyPeptide Group appears in nearly one in four qualified AI responses, but it is recommended in fewer than one in seven and named first in only 1.0% of observations. Buyers asking AI systems for a peptide API manufacturer are seeing PolyPeptide Group as an option, not as the answer. The difference between being shortlisted and being chosen first is the difference between entering a buyer's evaluation set and shaping it.

The next move is targeted correction of the prompt, page, and citation layers. The brand already has the presence to compete. What it needs is conversion: stronger owned answers on the prompts where it is already visible, a citation footprint that supports recommendation-stage placement, and monthly tracking to confirm whether the October recovery becomes a trend.

Core Metrics

Sentiment Score

Questions This Section Answers

• Why does a zero-negative mention count not mean PolyPeptide Group is being recommended?
• How is PolyPeptide Group's sentiment score calculated from its mentions?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For PolyPeptide Group in October 2026: (36 × 1 + 11 × 0 + 0 × -1) / 47 = 0.7660.

This matters because unclassified mention counts are misleading. A brand that appears in 47 responses but is framed negatively in half of them is not in the same position as a brand with 47 mentions and zero negative framing. PolyPeptide Group's zero negative mentions is a genuine strength, but it does not mean the brand is being recommended. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, and PolyPeptide Group's 0.7660 score reflects a clean but mid-pack framing position.

Sentiment by Platform

Questions This Section Answers

• Which platforms show the strongest positive sentiment signal for PolyPeptide Group?
• Where does PolyPeptide Group appear as context rather than recommendation?

Methodology

1. This report is a benchmark-based analysis of PolyPeptide Group's AI recommendation-stage visibility in Peptide API Manufacturing, produced from the October 2026 LLM Authority Index benchmark and supporting metrics aggregation.
2. The reporting window is October 2026, with comparisons to July 2026, August 2026, and September 2026 where the benchmark provides them.
3. Six AI/search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The October 2026 run collected 306 prompt-surface observations across 203 unique questions. Of those, 306 mentioned a tracked brand or competitor, 268 were relevant, 38 were irrelevant, and 200 qualified as the public denominator for brand metrics.
5. Seven brands were tracked: Bachem, AmbioPharm, PolyPeptide Group, CPC Scientific, Biosynth Peptide Division, CordenPharma Peptides, and CSBio.
6. All 200 qualified observations fell into the Brand Recommendation cluster. The Pricing & Value and Multi-Brand Comparison clusters contained zero qualified observations in October 2026.
7. Stage 0 extraction retained the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources.
8. A mention is counted when a brand appears in a qualified observation at all. Raw mention presence rate is the share of qualified observations in which the brand is mentioned.
9. A valid recommendation is counted when the dataset explicitly marks the brand as receiving a valid recommendation. Top-three rate, rank-one rate, and average recommended rank are calculated only on rank-eligible recommendations.
10. Brand-level percentages use the 200 qualified observations as the public denominator, not the 306 raw prompts collected or the 268 relevant prompts.
11. PolyPeptide Group's October 2026 metrics rest on 29 valid recommendations and 2 rank-one placements. Percentage movement on bases this small should be read as directional.
12. The benchmark does not measure market share, attributable sales, every possible AI response, organic-search ranking, social mention volume, private or sponsored channels, or causality from a metric movement alone. Source presence is evidence about the information environment and is not automatically proof that a source caused a recommendation.

See How AI Is Recommending Your Brand

The public benchmark shows where PolyPeptide Group stands in AI-generated recommendations across Peptide API Manufacturing. A company-level AI visibility audit maps the specific prompts, platforms, competitors, and citation sources that shape those recommendations, and identifies where the brand is being shortlisted versus chosen first.